Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
14 May 24
8-K
Singular Genomics Reports Recent Highlights and First Quarter 2024 Financial Results
14 May 24
ARS
2023 FY
Annual report to shareholders
18 Apr 24
DEFA14A
Additional proxy soliciting materials
18 Apr 24
DEF 14A
Definitive proxy
18 Apr 24
PRE 14A
Preliminary proxy
5 Apr 24
S-8
Registration of securities for employees
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
8-K
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2023 Financial Results
18 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2023 Revenue
8 Jan 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
Singular Genomics Reports Recent Highlights and Third Quarter 2023 Financial Results
14 Nov 23
8-K
Entry into a Material Definitive Agreement
14 Sep 23
10-Q
2023 Q2
Quarterly report
9 Aug 23
8-K
Singular Genomics Reports Recent Highlights and Second Quarter 2023 Financial Results
9 Aug 23
8-K
Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors
8 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
20 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
25 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Singular Genomics Reports Recent Highlights and First Quarter 2023 Financial Results
9 May 23
ARS
2022 FY
Annual report to shareholders
13 Apr 23
DEFA14A
Additional proxy soliciting materials
13 Apr 23
DEF 14A
Definitive proxy
13 Apr 23
S-8
Registration of securities for employees
2 Mar 23
10-K
2022 FY
Annual report
2 Mar 23
8-K
Singular Genomics Reports Recent Highlights and Fourth Quarter and Full Year 2022 Financial Results
2 Mar 23
8-K
Singular Genomics Reports Instrument Shipments and Preliminary Unaudited Fourth Quarter 2022 Revenue
9 Jan 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Singular Genomics Reports Recent Highlights and Third Quarter 2022 Financial Results
7 Nov 22
8-K
Entry into a Material Definitive Agreement
4 Oct 22
SC TO-I/A
Issuer tender offer statement (amended)
22 Aug 22
424B5
Prospectus supplement for primary offering
9 Aug 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Singular Genomics Reports Recent Highlights and Second Quarter 2022 Financial Results
9 Aug 22
EFFECT
Notice of effectiveness
28 Jul 22
DEFA14A
Additional proxy soliciting materials
25 Jul 22
8-K
Departure of Directors or Certain Officers
25 Jul 22
SC TO-I
Issuer tender offer statement
25 Jul 22
CORRESP
Correspondence with SEC
25 Jul 22
Latest ownership filings
4
Jyotsna Ghai
13 May 24
4
Dalen Meeter
13 May 24
4
Eli N. Glezer
13 May 24
4
Andrew Spaventa
13 May 24
4
Sam Ropp
19 Mar 24
4
Dalen Meeter
19 Mar 24
4
Eli N. Glezer
19 Mar 24
4
Andrew Spaventa
19 Mar 24
SC 13G/A
Glezer Eli N.
14 Feb 24
SC 13G/A
Spaventa Andrew
14 Feb 24
4
Jyotsna Ghai
13 Feb 24
4
Sam Ropp
13 Feb 24
4
Dalen Meeter
13 Feb 24
4
Eli N. Glezer
13 Feb 24
4
Andrew Spaventa
13 Feb 24
SC 13G/A
Flynn James E
12 Feb 24
SC 13G/A
Domain Partners IX, L.P.
25 Jan 24
4
Sam Ropp
18 Dec 23
4
Dalen Meeter
18 Dec 23
4
Eli N. Glezer
18 Dec 23
4
Andrew Spaventa
18 Dec 23
4
Andrew Spaventa
20 Nov 23
4
Eli N. Glezer
20 Nov 23
3
Jyotsna Ghai
9 Nov 23
4
Sam Ropp
15 Sep 23
4
Dalen Meeter
15 Sep 23
4
Eli N. Glezer
15 Sep 23
4
Andrew Spaventa
15 Sep 23
4
Sam Ropp
17 Aug 23
4
Kim P. Kamdar
15 Aug 23
144
Notice of proposed sale of securities
15 Aug 23
SC 13G/A
Flynn James E
14 Aug 23
144
Notice of proposed sale of securities
14 Aug 23
144
Notice of proposed sale of securities
11 Aug 23
4
Marcia Eisenberg
8 Aug 23
3
Marcia Eisenberg
8 Aug 23
4
Sam Ropp
20 Jun 23
4
Dalen Meeter
20 Jun 23
4
Eli N. Glezer
20 Jun 23
4
Andrew Spaventa
20 Jun 23